Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SCNI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.22
N/A
-4.57
vs -7.86
Q3.22
+126%
1.59
vs -6.07
Q4.22
N/A
-0.30
vs 2.64
Q1.23
N/A
-1.20
vs -4.15
Q2.23
N/A
-1.11
vs -4.57
Q3.23
N/A
-6.60
vs 1.59
Q4.23
N/A
-240.00
vs -0.30
Q1.24
+1100%
12
vs -1.20
Q2.24
N/A
-4.00
vs -1.11
Q3.24
+227%
8.4
vs -6.60
Sales Growth
YoY
Current
Estimates
Q2.22
NA
NA vs NA
Q3.22
NA
NA vs NA
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
284K vs NA
Q3.24
NA
168K vs NA
Return on Equity
QoQ
Q4.22
+30%
0.3
vs 0.4
Q1.23
+73%
0.73
vs 0.3
Q2.23
+53%
0.53
vs 0.73
Q3.23
-115%
-1.15
vs 0.53
Q4.23
+51%
0.51
vs -1.15
Q1.24
+42%
0.42
vs 0.51
Q2.24
+32%
0.32
vs 0.42
Q3.24
+105%
1.05
vs 0.32
Institutionnal Ownership
prnewswire.com
7 hours ago
prnewswire.com
7 hours ago
Relative Strength
SCNI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
NASDAQ
Unprofitable
Unprofitable
0.09Â ( 3.86%)
Relative Strenght
12
Volume Buzz
-92%
Earning Acce
Yes
Dist 52w H.
72%Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SCNI compares to sector?
SCNI
0x
